These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22788941)

  • 1. Optimizing treatments for lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Expert Rev Respir Med; 2012 Jun; 6(3):267-76. PubMed ID: 22788941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphangioleiomyomatosis: New Treatment Perspectives.
    Radzikowska E
    Lung; 2015 Aug; 193(4):467-75. PubMed ID: 25980593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphatic manifestations of lymphangioleiomyomatosis.
    Gupta R; Kitaichi M; Inoue Y; Kotloff R; McCormack FX
    Lymphology; 2014 Sep; 47(3):106-17. PubMed ID: 25420303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
    Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
    Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphangioleiomyomatosis.
    Xu KF; Xu W; Liu S; Yu J; Tian X; Yang Y; Wang ST; Zhang W; Feng R; Zhang T
    Semin Respir Crit Care Med; 2020 Apr; 41(2):256-268. PubMed ID: 32279296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
    Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
    Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lymphangioleiomyomatosis - new concepts on pathogenesis, diagnosis and treatment].
    Sobiecka M
    Wiad Lek; 2016; 69(2 Pt 1):123-9. PubMed ID: 27421126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphangioleiomyomatosis: what do we know and what are we looking for?
    Harari S; Torre O; Moss J
    Eur Respir Rev; 2011 Mar; 20(119):34-44. PubMed ID: 21357890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.
    Glasgow CG; Steagall WK; Taveira-Dasilva A; Pacheco-Rodriguez G; Cai X; El-Chemaly S; Moses M; Darling T; Moss J
    Respir Med; 2010 Jul; 104 Suppl 1(Suppl 1):S45-58. PubMed ID: 20630348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
    Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
    Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
    J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SUCCESSFUL TREATMENT OF PULMONARY AND LYMPHATIC MANIFESTATIONS OF LYMPHANGIOLEIOMYOMATOSIS WITH SIROLIMUS.
    Hecimovic A; Jakopovic M; Pavlisa G; Jankovic M; Vukic-Dugac A; Redzepi G; Brcic L; Samarzija M; Gupta N
    Lymphology; 2015 Jun; 48(2):97-102. PubMed ID: 26714374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted approaches toward understanding and treating pulmonary lymphangioleiomyomatosis (LAM).
    Hammes SR; Krymskaya VP
    Horm Cancer; 2013 Apr; 4(2):70-7. PubMed ID: 23184699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
    Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
    Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
    Liu HJ; Krymskaya VP; Henske EP
    Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
    Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
    PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.
    Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK
    Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.